医学界心血管频道|心衰治疗新时代,“乘风破浪”的β受体阻滞剂——卡维地洛( 三 )


[5] Cleland, J.G., et al. Myocardial Viability as a Determinant of the Ejection Fraction Response to Carvedilol in Patients With Heart Failure (CHRISTMAS Trial): Randomised Controlled Trial. Lancet, 2003. 362(9377): p. 14-21.
[6] Michel Komajda., et al. Tolerability of Carvedilol and ACE-Inhibition in Mild Heart Failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).Eur J of Heart Failure.2004.6(4):467-475
[7] Dargie, H.J. Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left-Ventricular Dysfunction: The CAPRICORN Randomised Trial. Lancet, 2001. 357(9266): p. 1385-90.
[8] Paker M The Effect of Carvedilol on Morbidity and Mortality in Patients With Chronic Heart Failure. U.S. Carvedilol Heart Failure Study Group. N Eng J Med,1996,334:1349-1355.
[9] Poole-Wilson, P.A., et al. Comparison of Carvedilol and Metoprolol on Clinical Outcomes in Patients With Chronic Heart Failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised Controlled Trial. Lancet, 2003. 362(9377): p. 7-13.
[10]Packer M et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med. 2001;344(22):1651-8
【医学界心血管频道|心衰治疗新时代,“乘风破浪”的β受体阻滞剂——卡维地洛】 点个分享 , 让更多人知道!


推荐阅读